References
- Little U, Buchanan F, Harkin-Jones E, McCaigue M, Farrar D, Dickson G. (2009). Accelerated degradation behaviour of poly(epsilon-caprolactone) via melt blending with poly(aspartic acid-co-lactide) (PAL). Polym Degrad Stab, 94:213–220.
- Diab R, Hamoudeh M, Boyron O, Elaissari A, Fessi H. (2010). Microencapsulation of cytarabine using poly(ethylene glycol)-poly(epsilon-caprolactone) diblock copolymers as surfactant agents. Drug Dev Ind Pharm, 36:456–469.
- Sinha VR, Khosla L. (1998). Bioabsorbable polymers for implantable therapeutic systems. Drug Dev Ind Pharm, 24:1129–1138.
- Sinha VR, Bansal K, Kaushik R, Kumria R, Trehan A. (2004). Poly-epsilon-caprolactone microspheres and nanospheres: an overview. Int J Pharm, 278:1–23.
- Zhang Y, Zhang Y, Guo S, Huang W. (2009). Tyrosine kinase inhibitor loaded PCL microspheres prepared by S/O/W technique using ethanol as pretreatment agent. Int J Pharm, 369:19–23.
- Fialho SL, Behar-Cohen F, Silva-Cunha A. (2008). Dexamethasone-loaded poly(epsilon-caprolactone) intravitreal implants: a pilot study. Eur J Pharm Biopharm, 68:637–646.
- Crowley MM, Zhang F, Repka MA, Thumma S, Upadhye SB, Battu SK et al. (2007). Pharmaceutical applications of hot-melt extrusion: part I. Drug Dev Ind Pharm, 33:909–926.
- Repka MA, Battu SK, Upadhye SB, Thumma S, Crowley MM, Zhang F et al. (2007). Pharmaceutical applications of hot-melt extrusion: Part II. Drug Dev Ind Pharm, 33:1043–1057.
- Altpeter H, Bevis MJ, Grijpma DW, Feijen J. (2004). Non-conventional injection molding of poly(lactide) and poly(epsilon-caprolactone) intended for orthopedic applications. J Mater Sci Mater Med, 15:175–184.
- Siegel SJ, Kahn JB, Metzger K, Winey KI, Werner K, Dan N. (2006). Effect of drug type on the degradation rate of PLGA matrices. Eur J Pharm Biopharm, 64:287–293.
- Amass W, Amass A, Tighe B. (1998). A review of biodegradable polymers: Uses, current developments in the synthesis and characterization of biodegradable polyesters, blends of biodegradable polymers and recent advances in biodegradation studies. Polym Int, 47:89–144.
- Higuchi T. (1961). Rate of release of medicaments from ointment bases containing drugs in suspension. J Pharm Sci, 50:874–875.
- Siepmann J, Göpferich A. (2001). Mathematical modeling of bioerodible, polymeric drug delivery systems. Adv Drug Deliv Rev, 48:229–247.
- Freiberg S, Zhu XX. (2004). Polymer microspheres for controlled drug release. Int J Pharm, 282:1–18.
- Holy CE, Dang SM, Davies JE, Shoichet MS. (1999). In vitro degradation of a novel poly(lactide-co-glycolide) 75/25 foam. Biomaterials, 20:1177–1185.
- Lu L, Peter SJ, Lyman MD, Lai HL, Leite SM, Tamada JA et al. (2000). In vitro and in vivo degradation of porous poly(DL-lactic-co-glycolic acid) foams. Biomaterials, 21:1837–1845.
- Narasimhan B, Peppas NA. (1997). Molecular analysis of drug delivery systems controlled by dissolution of the polymer carrier. J Pharm Sci, 86:297–304.
- Miller-Chou BA, Koenig JL. (2003). A review of polymer dissolution. Prog Polym Sci, 28:1223–1270.
- Yoon JS, Jung HW, Kim MN, Park ES. (2000). Diffusion coefficient and equilibrium solubility of water molecules in biodegradable polymers. J Appl Polym Sci, 77:1716–1722.
- Rosenberg RT, Siegel SJ, Dan N. (2008). Release of highly hydrophilic drugs from poly(epsilon-caprolactone) matrices. J Appl Polym Sci, 107:3149–3156.
- Frank A, Rath SK, Venkatraman SS. (2005). Controlled release from bioerodible polymers: effect of drug type and polymer composition. J Control Release, 102:333–344.
- Kiortsis S, Kachrimanis K, Broussali T, Malamataris S. (2005). Drug release from tableted wet granulations comprising cellulosic (HPMC or HPC) and hydrophobic component. Eur J Pharm Biopharm, 59:73–83.
- Rosenberg R, Devenney W, Siegel S, Dan N. (2007). Anomalous release of hydrophilic drugs from poly(epsilon-caprolactone) matrices. Mol Pharm, 4:943–948.
- Li C, Cheng L, Zhang Y, Guo S, Wu W. (2010). Effects of implant diameter, drug loading and end-capping on praziquantel release from PCL implants. Int J Pharm, 386:23–29.
- Longley DB, Harkin DP, Johnston PG. (2003). 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer, 3:330–338.
- Wang J, Hu Y, Li L, Jiang T, Wang S, Mo F. (2010). Indomethacin-5-fluorouracil-methyl ester dry emulsion: a potential oral delivery system for 5-fluorouracil. Drug Dev Ind Pharm, 36:647–656.
- National Pharmacopoeia Committee of PRC. (2005a). Pharmacopoeia of People’s Republic of China, Vol. II. Beijing, China: Chemical Industry Press, p. 395.
- National Pharmacopoeia Committee of PRC. (2005b). Pharmacopoeia of People’s Republic of China, Vol. II. Beijing, China: Chemical Industry Press, Appendix pp. 75–76.
- Cheng L, Guo S, Wu W. (2009). Characterization and in vitro release of praziquantel from poly(epsilon-caprolactone) implants. Int J Pharm, 377:112–119.
- Sairam M, Babu VR, Vijaya B, Naidu K, Aminabhavi TM. (2006). Encapsulation efficiency and controlled release characteristics of crosslinked polyacrylamide particles. Int J Pharm, 320:131–136.
- Wang S, Guo S, Cheng L. (2008). Disodium norcantharidate loaded poly(epsilon-caprolactone) microspheres I. Preparation and evaluation. Int J Pharm, 350:130–137.
- Costa P, Sousa Lobo JM. (2001). Modeling and comparison of dissolution profiles. Eur J Pharm Sci, 13:123–133.
- Gao H, Gu Y, Ping Q. (2007). The implantable 5-fluorouracil-loaded poly(l-lactic acid) fibers prepared by wet-spinning from suspension. J Control Release, 118:325–332.
- Ritger PL, Peppas NA. (1987). A simple equation for description of solute release I. Fickian and non-Fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs. J Controlled Release, 5:23–36.
- Phaechamud T, Ritthidej GC. (2007). Sustained-release from layered matrix system comprising chitosan and xanthan gum. Drug Dev Ind Pharm, 33:595–605.